B-LCL-HROG02 Cells

B-LCL-HROG02 is a human Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell line (B-LCL) established from the peripheral blood of a 68-year-old Caucasian male gastric cancer patient within the HROG biobank series, the gastric cancer counterpart of the HROC colorectal cancer B-LCL collection. EBV-mediated in vitro immortalization of primary peripheral blood B lymphocytes generated a stably proliferating suspension cell line with lymphoblast-like morphology. HROG02 cells constitutively express EBV latency antigens (EBNA-1, -2, -3, LMP-1, -2) and high levels of HLA class I and II molecules, co-stimulatory molecules CD80 and CD86, adhesion molecules CD54 and CD58, and B cell markers CD19, CD20, and CD23.
B-LCL-HROG02 is applied in T cell and NK cell functional assays, HLA typing, mixed lymphocyte reactions, antigen presentation studies, and CTL induction protocols. Within the HROG patient-matched biobank, it provides a defined immunological reference for gastric cancer research, enabling autologous or allogeneic studies of tumor-associated immune responses. The line supports investigations of gastric cancer-specific T cell reactivity and patient-matched immune assay systems relevant to gastric tumor immunology.